Ouro

Ouro Medicines is a clinical-stage biotechnology company dedicated to developing immune reset therapeutics for chronic immune-mediated diseases. Launched in early 2025 through a collaboration between Monograph Capital and GSK, the company utilizes T cell engagers (TCEs) to precisely deplete pathogenic B cell populations, aiming to achieve durable remission without long-term immunosuppression. Its lead candidate, OM336 (gamgertamig), is a BCMAxCD3 bispecific antibody licensed from Keymed Biosciences that has demonstrated transformative efficacy in severe antibody-mediated orphan diseases like autoimmune hemolytic anemia. In March 2026, Gilead Sciences announced its acquisition of Ouro Medicines to integrate its promising TCE pipeline into Gilead's inflammation and autoimmune portfolio.